Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years.


Journal

Breast cancer research : BCR
ISSN: 1465-542X
Titre abrégé: Breast Cancer Res
Pays: England
ID NLM: 100927353

Informations de publication

Date de publication:
29 09 2020
Historique:
received: 17 02 2020
accepted: 10 09 2020
entrez: 30 9 2020
pubmed: 1 10 2020
medline: 14 1 2021
Statut: epublish

Résumé

A decrease in breast density due to tamoxifen preventive therapy might indicate greater benefit from the drug. It is not known whether mammographic density continues to decline after 1 year of therapy, or whether measures of breast density change are sufficiently stable for personalised recommendations. Mammographic density was measured annually over up to 5 years in premenopausal women with no previous diagnosis of breast cancer but at increased risk of breast cancer attending a family-history clinic in Manchester, UK (baseline 2010-2013). Tamoxifen (20 mg/day) for prevention was prescribed for up to 5 years in one group; the other group did not receive tamoxifen and were matched by age. Fully automatic methods were used on mammograms over the 5-year follow-up: three area-based measures (NN-VAS, Stratus, Densitas) and one volumetric (Volpara). Additionally, percentage breast density at baseline and first follow-up mammograms was measured visually. The size of density declines at the first follow-up mammogram and thereafter was estimated using a linear mixed model adjusted for age and body mass index. The stability of density change at 1 year was assessed by evaluating mean squared error loss from predictions based on individual or mean density change at 1 year. Analysis used mammograms from 126 healthy premenopausal women before and as they received tamoxifen for prevention (median age 42 years) and 172 matched controls (median age 41 years), with median 3 years follow-up. There was a strong correlation between percentage density measures used on the same mammogram in both the tamoxifen and no tamoxifen groups (all correlation coeficients > 0.8). Tamoxifen reduced mean breast density in year 1 by approximately 17-25% of the inter-quartile range of four automated percentage density measures at baseline, and from year 2, it decreased further by approximately 2-7% per year. Predicting change at 2 years using individual change at 1 year was approximately 60-300% worse than using mean change at 1year. All measures showed a consistent and large average tamoxifen-induced change in density over the first year, and a continued decline thereafter. However, these measures of density change at 1 year were not stable on an individual basis.

Sections du résumé

BACKGROUND
A decrease in breast density due to tamoxifen preventive therapy might indicate greater benefit from the drug. It is not known whether mammographic density continues to decline after 1 year of therapy, or whether measures of breast density change are sufficiently stable for personalised recommendations.
METHODS
Mammographic density was measured annually over up to 5 years in premenopausal women with no previous diagnosis of breast cancer but at increased risk of breast cancer attending a family-history clinic in Manchester, UK (baseline 2010-2013). Tamoxifen (20 mg/day) for prevention was prescribed for up to 5 years in one group; the other group did not receive tamoxifen and were matched by age. Fully automatic methods were used on mammograms over the 5-year follow-up: three area-based measures (NN-VAS, Stratus, Densitas) and one volumetric (Volpara). Additionally, percentage breast density at baseline and first follow-up mammograms was measured visually. The size of density declines at the first follow-up mammogram and thereafter was estimated using a linear mixed model adjusted for age and body mass index. The stability of density change at 1 year was assessed by evaluating mean squared error loss from predictions based on individual or mean density change at 1 year.
RESULTS
Analysis used mammograms from 126 healthy premenopausal women before and as they received tamoxifen for prevention (median age 42 years) and 172 matched controls (median age 41 years), with median 3 years follow-up. There was a strong correlation between percentage density measures used on the same mammogram in both the tamoxifen and no tamoxifen groups (all correlation coeficients > 0.8). Tamoxifen reduced mean breast density in year 1 by approximately 17-25% of the inter-quartile range of four automated percentage density measures at baseline, and from year 2, it decreased further by approximately 2-7% per year. Predicting change at 2 years using individual change at 1 year was approximately 60-300% worse than using mean change at 1year.
CONCLUSIONS
All measures showed a consistent and large average tamoxifen-induced change in density over the first year, and a continued decline thereafter. However, these measures of density change at 1 year were not stable on an individual basis.

Identifiants

pubmed: 32993747
doi: 10.1186/s13058-020-01340-4
pii: 10.1186/s13058-020-01340-4
pmc: PMC7523310
doi:

Substances chimiques

Antineoplastic Agents, Hormonal 0
Tamoxifen 094ZI81Y45

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

101

Subventions

Organisme : Cancer Research UK
ID : C569/A16891
Pays : United Kingdom
Organisme : National Institute for Health Research
ID : PB-PG-0110-21342
Pays : International
Organisme : Genesis Breast Cancer Prevention
ID : GA09-001/GA10-002
Pays : International
Organisme : Department of Health
ID : PB-PG-0110-21342
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 5032
Pays : United Kingdom

Références

J Med Imaging (Bellingham). 2019 Jul;6(3):031405
pubmed: 30746393
J Clin Oncol. 2013 Jun 20;31(18):2249-56
pubmed: 23610119
Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):212-6
pubmed: 26545407
Breast Cancer Res. 2013;15(4):R57
pubmed: 23876209
Lancet. 2013 May 25;381(9880):1827-34
pubmed: 23639488
Breast Cancer Res. 2018 Sep 4;20(1):103
pubmed: 30180877
Breast. 2019 Oct;47:62-76
pubmed: 31352313
Breast Cancer Res. 2018 Feb 05;20(1):10
pubmed: 29402289
J Clin Oncol. 2016 Sep 1;34(25):3069-103
pubmed: 27217461
Breast Cancer Res. 2012 Jul 06;14(4):R102
pubmed: 22770227
BMJ. 1995 Mar 11;310(6980):633
pubmed: 7703752
Cancer Epidemiol Biomarkers Prev. 2017 Jun;26(6):930-937
pubmed: 28148596
Breast Cancer Res Treat. 2013 Dec;142(3):559-67
pubmed: 24233999
Acta Oncol. 2015 Mar;54(3):349-60
pubmed: 25383451
JAMA Oncol. 2018 Apr 1;4(4):476-482
pubmed: 29346471
JNCI Cancer Spectr. 2019 Jan 29;2(4):pky071
pubmed: 31360886
Breast Cancer Res. 2018 Mar 22;20(1):23
pubmed: 29566728
J Natl Cancer Inst. 2011 May 4;103(9):744-52
pubmed: 21483019
Breast Cancer Res Treat. 2018 Jun;169(2):371-379
pubmed: 29392583
Lancet. 2011 Aug 27;378(9793):771-84
pubmed: 21802721
J Natl Cancer Inst. 2015 Feb 06;107(3):
pubmed: 25663687

Auteurs

Adam R Brentnall (AR)

Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK.

Ruth Warren (R)

Department of Radiology, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK.

Elaine F Harkness (EF)

Division of Informatics, Imaging and Data Sciences, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
Prevent Breast Cancer Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, M23 9LT, UK.

Susan M Astley (SM)

Division of Informatics, Imaging and Data Sciences, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
Prevent Breast Cancer Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, M23 9LT, UK.
Manchester Breast Centre, Manchester Cancer Research Centre, University of Manchester, Manchester, M20 4BX, UK.

Julia Wiseman (J)

Prevent Breast Cancer Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, M23 9LT, UK.

Jill Fox (J)

Prevent Breast Cancer Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, M23 9LT, UK.

Lynne Fox (L)

Prevent Breast Cancer Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, M23 9LT, UK.

Mikael Eriksson (M)

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.

Per Hall (P)

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.

Jack Cuzick (J)

Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK.

D Gareth Evans (DG)

Prevent Breast Cancer Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, M23 9LT, UK.
Manchester Breast Centre, Manchester Cancer Research Centre, University of Manchester, Manchester, M20 4BX, UK.
NW Genomic Laboratory Hub, Manchester Centre for Genomic Medicine, Manchester University NHS Foundation Trust, Manchester, M13 9WL, UK.
Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.

Anthony Howell (A)

Prevent Breast Cancer Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, M23 9LT, UK. anthony.howell@manchester.ac.uk.
Manchester Breast Centre, Manchester Cancer Research Centre, University of Manchester, Manchester, M20 4BX, UK. anthony.howell@manchester.ac.uk.
Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, M13 9PL, UK. anthony.howell@manchester.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH